Mental Health Assessment and Prescribing by Alberta Pharmacists — MAP-AP  

Major Depressive Disorder Clinical Trial

Official title: Mental Health Assessment and Prescribing by Alberta Pharmacists (MAP-AP)

Status Recruiting

Clinical Trial Summary

This is a clinical trial evaluating the experimental intervention of enhanced pharmacist care by pharmacists with additional prescribing authorization (APA) in Alberta, for patients newly diagnosed with Major Depressive Disorder (MDD) and Generalized Anxiety Disorder (GAD).

Clinical Trial Description

Primary objective

-To evaluate the effect of enhanced pharmacist care possible by community pharmacists with APA in comparison with usual care (standard pharmacist care and physician care) for patients with MDD and/or GAD initiated on pharmacotherapy, with focus on interventions that include:

i) monitoring (lab ordering and interpretation, clinical monitoring of MDD and GAD) ii) patient education iii) referral facilitation (in collaboration with prescribing physician) iv) prescribing (dose adjustment and the addition of adjunctive medication)

Secondary objectives

• To evaluate the effect of APA pharmacist interventions on:

i)Clinical:

• The rate of achieving clinical response and remission of MDD and/or GAD compared to usual care (using PHQ-9/GAD-7)

• Change in the mean PHQ-9 and GAD-7 score

• Cognitive and functional impairment related to MDD and/or GAD

• The occurrence of relapse of depression and/or anxiety

• The proportion of patients receiving appropriate and optimized depression and anxiety medication

• Patient complaints and/or experiences of medication-related side effects during treatment for MDD and/or GAD (i.e. GI intolerance, dizziness, weight gain)

ii) Process:

• The impact of the interventions on patient satisfaction and quality of life impact (Patient survey)

• Assure sustainability by exploring enabling (i.e. pharmacist reimbursement framework) and potential barrier forces (i.e. pharmacist training in managing patients with MDD and GAD) ;

Related Conditions & MeSH terms

• Anxiety Disorders
• Depression
• Depressive Disorder
• Depressive Disorder, Major
• Generalized Anxiety Disorder
• Major Depressive Disorder
• Pharmacist-Patient Relations

• NCT number: NCT04410575
• Study type: Interventional
• Source: University of Alberta
• Contact: Yazid Al Hamarneh, BSc (Pharm), PhD, CDM
• Phone: (780) 492-9608
• Email: yazid.alhamarneh@ualberta.ca
• Status: Recruiting
• Phase: N/A
• Start date: March 22, 2023
• Completion date: December 30, 2024